Suncoast Equity Management purchased a new position in TuHURA Biosciences (NASDAQ:HURA - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 102,997 shares of the company's stock, valued at approximately $421,000. Suncoast Equity Management owned 0.24% of TuHURA Biosciences as of its most recent filing with the Securities and Exchange Commission.
Separately, Apollon Wealth Management LLC purchased a new stake in TuHURA Biosciences during the fourth quarter worth $253,000. 0.62% of the stock is currently owned by institutional investors.
TuHURA Biosciences Stock Performance
NASDAQ HURA opened at $3.30 on Friday. The business has a fifty day moving average price of $4.41. TuHURA Biosciences has a 12-month low of $2.84 and a 12-month high of $14.60.
Analyst Upgrades and Downgrades
A number of research analysts have recently issued reports on HURA shares. Rodman & Renshaw initiated coverage on TuHURA Biosciences in a report on Thursday, December 19th. They issued a "buy" rating and a $11.00 price target on the stock. RODMAN&RENSHAW upgraded TuHURA Biosciences to a "strong-buy" rating in a research note on Thursday, December 19th. Finally, Maxim Group began coverage on shares of TuHURA Biosciences in a report on Tuesday, November 5th. They issued a "buy" rating and a $15.00 target price for the company.
Check Out Our Latest Report on TuHURA Biosciences
About TuHURA Biosciences
(
Free Report)
TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
Featured Stories
Want to see what other hedge funds are holding HURA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TuHURA Biosciences (NASDAQ:HURA - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider TuHURA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TuHURA Biosciences wasn't on the list.
While TuHURA Biosciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
